Tags

Type your tag names separated by a space and hit enter

A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis.
J Dermatolog Treat. 2002 Jun; 13(2):51-60.JD

Abstract

BACKGROUND

The association between seborrhoeic dermatitis and dandruff and the yeast Malassezia furfur is well recognized. Symptoms include scalp itchiness and scaling. Due to its antimycotic activity, ciclopirox olamine is established as an effective treatment for these scalp conditions. Salicylic acid has keratolytic properties and aids in the removal of scales.

OBJECTIVE

To compare the therapeutic efficacy of a shampoo containing 1.5% ciclopirox olamine and 3% salicylic acid (CPO/SA) with Nizoral (2.0% ketoconazole shampoo) in a study involving 154 subjects with dandruff - 70 of whom also had seborrhoeic dermatitis of the scalp. Nizoral is currently a registered treatment for dandruff and seborrhoeic dermatitis.

METHODS

The shampoos were used three times week for 4 weeks, with 2-week washout and follow-up periods. Clinical and self-assessments were made throughout treatment and after follow-up (day 43). Within and between-treatment assessments of signs and symptoms were analysed.

RESULTS

In the two groups, seborrhoeic dermatitis and dandruff improved significantly throughout treatment, with lower clinical and self-assessment scores at both the end of treatment (day 29) and follow-up (day 43). Only the subjects treated with CPO/SA shampoo showed a significant reduction in the itching of seborrhoeic dermatitis at these times.

CONCLUSION

The study demonstrated that both CPO/SA and Nizoral were safe and effective in the treatment of dandruff and seborrhoeic dermatitis.

Links

Publisher Full Text

Authors+Show Affiliations

Squire RA
PPD Development, Chelmsford, Essex, UK.
Goode K
No affiliation info available

MeSH

Administration, CutaneousAdolescentAdultAgedAntifungal AgentsChildCiclopiroxDermatitis, SeborrheicFemaleHumansKetoconazoleMaleMiddle AgedPatient SatisfactionPyridonesSafetySalicylic AcidScalp DermatosesSingle-Blind MethodStatistics, NonparametricTreatment Outcome

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

12060502

Citation

Squire, R A., and K Goode. "A Randomised, Single-blind, Single-centre Clinical Trial to Evaluate Comparative Clinical Efficacy of Shampoos Containing Ciclopirox Olamine (1.5%) and Salicylic Acid (3%), or Ketoconazole (2%, Nizoral) for the Treatment of Dandruff/seborrhoeic Dermatitis." The Journal of Dermatological Treatment, vol. 13, no. 2, 2002, pp. 51-60.
Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatolog Treat. 2002;13(2):51-60.
Squire, R. A., & Goode, K. (2002). A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. The Journal of Dermatological Treatment, 13(2), 51-60.
Squire RA, Goode K. A Randomised, Single-blind, Single-centre Clinical Trial to Evaluate Comparative Clinical Efficacy of Shampoos Containing Ciclopirox Olamine (1.5%) and Salicylic Acid (3%), or Ketoconazole (2%, Nizoral) for the Treatment of Dandruff/seborrhoeic Dermatitis. J Dermatolog Treat. 2002;13(2):51-60. PubMed PMID: 12060502.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. AU - Squire,R A, AU - Goode,K, PY - 2002/6/13/pubmed PY - 2002/8/7/medline PY - 2002/6/13/entrez SP - 51 EP - 60 JF - The Journal of dermatological treatment JO - J Dermatolog Treat VL - 13 IS - 2 N2 - BACKGROUND: The association between seborrhoeic dermatitis and dandruff and the yeast Malassezia furfur is well recognized. Symptoms include scalp itchiness and scaling. Due to its antimycotic activity, ciclopirox olamine is established as an effective treatment for these scalp conditions. Salicylic acid has keratolytic properties and aids in the removal of scales. OBJECTIVE: To compare the therapeutic efficacy of a shampoo containing 1.5% ciclopirox olamine and 3% salicylic acid (CPO/SA) with Nizoral (2.0% ketoconazole shampoo) in a study involving 154 subjects with dandruff - 70 of whom also had seborrhoeic dermatitis of the scalp. Nizoral is currently a registered treatment for dandruff and seborrhoeic dermatitis. METHODS: The shampoos were used three times week for 4 weeks, with 2-week washout and follow-up periods. Clinical and self-assessments were made throughout treatment and after follow-up (day 43). Within and between-treatment assessments of signs and symptoms were analysed. RESULTS: In the two groups, seborrhoeic dermatitis and dandruff improved significantly throughout treatment, with lower clinical and self-assessment scores at both the end of treatment (day 29) and follow-up (day 43). Only the subjects treated with CPO/SA shampoo showed a significant reduction in the itching of seborrhoeic dermatitis at these times. CONCLUSION: The study demonstrated that both CPO/SA and Nizoral were safe and effective in the treatment of dandruff and seborrhoeic dermatitis. SN - 0954-6634 UR - https://www.unboundmedicine.com/medline/citation/12060502/A_randomised_single_blind_single_centre_clinical_trial_to_evaluate_comparative_clinical_efficacy_of_shampoos_containing_ciclopirox_olamine__1_5__and_salicylic_acid__3__or_ketoconazole__2_Nizoral__for_the_treatment_of_dandruff/seborrhoeic_dermatitis_ L2 - https://www.tandfonline.com/doi/full/10.1080/095466302317584395 DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓13]

Related Citations

More